Research
Molecular
Dapagliflozin is a selective SGLT2 inhibitor approved to improve glycemic control in adults with type 2 diabetes.
Dapagliflozin can be considered as a treatment option for managing blood sugar levels in adults with type 2 diabetes.
StrongSupportsmedium confidence
Dapagliflozin (Farxiga, AstraZeneca) is a selective SGLT2 inhibitor approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Why this rating
The claim is supported by clinical trial data mentioned in the abstract.
Source
Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
Eva Vivian · American Journal of Health-System Pharmacy · 2015
reviewCited 44×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →